Close
FINDING CURES TOGETHER<sup>SM</sup>
  • Home
  • Funding
  • SU2C Canada-Canadian Breast Cancer Foundation Breast Cancer Team Subcommittee
Laura van ‘t Veer, PhD

Laura van ‘t Veer, PhD
(2014-present)
Professor of Laboratory Medicine; Program Leader of the Breast Oncology Program and Director of Applied Genomics
UCSF Helen Diller Family Comprehensive Cancer Center​
San Francisco, California

​Laura van 't Veer, PhD is Professor of Laboratory Medicine at the University California San Francisco (UCSF). She is the Program Leader of the Breast Oncology Program and Director of Applied Genomics with the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. van 't Veer is a world renowned Molecular Biologist and inventor of MammaPrint®. Her research focuses on personalized medicine, to advance patient management based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. Her current research is aimed to understand the molecular basis for early response to therapy as a surrogate for outcome prediction.

Dr. van 't Veer is the Biomarker Committee Chair for the Foundation of NIH sponsored multicenter adaptive clinical trial I-SPY 2, overseeing the processes for FDA-IDE biomarker usage and qualifying biomarker companion diagnostic testing. She served 2010-2014 as Board member of the American Association of Cancer Research. Since 2014 she is the AACR chair of the Diagnostic Policy Committee.

Dr. van 't Veer received the 2007 European Society of Medical Oncology (ESMO) life-time achievement award for translational research in breast cancer, the European Union Women Innovator Award, 2nd prize in 2014, and the prestigious European Inventor Award 2015 for small and medium-sized enterprises.

Dr. van 't Veer received her PhD in Medicine for a dissertation on oncogene activation and tumorigenesis in 1989 at the University of Leiden. She had postdoctoral fellowships at the Cancer Center of Harvard Medical School and Massachusetts General Hospital in Boston (1989-1991), followed by the Division of Molecular Carcinogenesis at The Netherlands Cancer Institute (1992-1993). She then joined The Netherlands Cancer Institute as a Molecular Biologist in the Department of Pathology. At the institute she assumed increasing responsibilities, starting with the initiation and leadership of the Departments of Molecular Pathology and Genetic Counseling, culminating with her appointment as the Head of Diagnostic Oncology, overseeing the clinical work and associated research. In 2003 she was one of the founders of the Netherlands Cancer Institute spin-off, the molecular profiling company Agendia. At Agendia she led the effort by which MammaPrint® obtained the first FDA 510K 'In Vitro Diagnostic Multigene Index Assay' (IVDMIA) clearance in 2007.